INTROduCTION Streptococcus pneumoniae (S. pneumoniae) is one of the most common bacterial pathogens in community-acquired pneumonia. However, nosocomial pneumococcal infections are more and more widely observed.
INTROduCTION
Streptococcus pneumoniae (S. pneumoniae) causes a wide spectrum of community-acquired diseases, ranging from common upper respiratory tract infections, through pneumonia, to very severe invasive infections including meningitis and sepsis. Although epidemics or outbreaks of pneumococcal disease have been described, the vast majority of pneumococcal diseases occur as sporadic cases. [1] [2] [3] [4] Outbreaks are rare and restricted to crowded settings, such as day care centers, nursing homes, military camps, and prisons.
4-8 Hospital outbreaks have also been reported. However, they are typically prolonged, lasting over extensive periods of time such as weeks, months, or even years.
9-11 We report a nosocomial outbreak caused by multidrug--resistant S. pneumoniae isolates, which occurred within 10 days in a single ward of a pulmonary diseases hospital. the outbreak; however, in most cases, the prior treatment did not cover the susceptibility profile of the infecting S. pneumoniae (TAbLE) .
Prior to the outbreak, 5 patients were already hospitalized due to acute exacerbation of COPD (III-IV Global Initiative for Chronic Obstructive Lung Disease in respiratory failure) and, in 1 case, due to asthma exacerbation; 4 of these patients were hospitalized at least for 8 days. One male patient (case 2) was previously hospitalized for 25 days and then discharged. However, in the evening of the same day, he returned to the hospital with progressive difficulty in breathing, weakness, and a temperature above 39oC. A similar situation occurred with 1 female patient (case 6), who was readmitted to the same hospital with new symptoms 2 days after discharge. Finally, she died from respiratory failure, 38 days after the appearance of symptoms connected with pneumococcal infection due to a serious primary condition.
Control of the outbreak On January 12, the following infection control measures were implemented to limit the spread of the outbreak: isolation of infected patients, reinforced sanitary regimen (disposable masks and coats for patients and the personnel, use of bactericidal lamps, instruction of patients concerning hand washing and disinfection), limitations for visitors to the ward and enhanced supervision of the compliance with the above recommendations by the hospital infection control team. Beyond that date, the outbreak was eradicated since no further nosocomial transmission of pneumococci was observed. mutation in gyrA and the S82F mutation in parC (the R6 numbering). Additionally, parC and parE harbored the K140N and the I460V polymorphisms, respectively; no changes were observed in the QRDR of gyrB.
dIsCussION Infections caused by S. pneumoniae are most prevalent in the extreme age groups and account for more deaths than any other vaccine--preventable bacterial disease. 1-2 Although pneumococcal infections are mostly sporadic community-acquired cases, they may occur as outbreaks, mainly in institutional settings.
4-8 The short-term outbreak described here was unusual because it encompassed patients already receiving antimicrobial therapy due to the primary disease. However, it did not prevent the outbreak because in most cases it did not cover multidrug-resistant S. pneumoniae responsible for the infection in all patients. The outbreak was noted due to the vigilance of doctors and microbiologists when new symptoms appeared in the second and further patients of a single ward along with the isolation of characteristic multidrug-resistant pneumococci.
The outbreak was confirmed by laboratory analyses. Five pneumococcal isolates available for further testing shared the genotype and serotype, and together with the isolate from the index case displayed a very similar drug-resistance profile, thus strongly indicating their nosocomial PATIENTs ANd mEThOds Pneumococcal isolates were cultured from sputum (evaluated by the number of white blood cells and epithelial cells, together with the presence of mucus threads) or bronchoalveolar lavage (BALF). All isolates were identified based on typical morphology, Gram stain, susceptibility to optochin (bioMerieux, France), and bile solubility. 12 Serotypes of S. pneumoniae were determined by latex agglutination using the Pneumotest-Latex kit (Statens Serum Institut, Denmark). Minimal inhibitory concentrations (MICs) for penicillin, amoxicillin, cefotaxime, erythromycin, azithromycin, clindamycin, ciprofloxacin, levofloxacin, moxifloxacin, tetracycline, rifampicin, chloramphenicol, linezolid, and vancomycin were determined by Etest (AB Biodisk, Sweden) or M.I.C. Evaluators (Oxoid, United Kingdom) according to the manufacturers' instructions. Susceptibility to telithromycin was evaluated by the disc diffusion method (15 µg, Becton Dickinson, United States). The results were interpreted according to the Clinical and Laboratory Standards Institute guidelines, and isolates with MIC 4 mg/l of ciprofloxacin were considered nonsusceptible.
13,14 The quality control strain was S. pneumoniae ATCC 49 619.
The relatedness among isolates was evaluated by pulsed-field gel electrophoresis (PFGE) of SmaI-digested chromosomal DNA, as previously described.
15 A representative of the isolates was characterized by multilocus sequence typing (MLST), multiple loci variable number of tandem repeats analysis (MLVA), and sequencing of the quinolone-determining regions (QRDRs) in the gyrA, gyrB, parC, and parE genes.
16-18
Outbreak description The outbreak occurred at the Department of Pulmonary Diseases and Respiratory Failure in the Regional Centre of Pulmonology in Bydgoszcz, in a 28-bed respiratory ward, where from 61% to 100% of beds were occupied at the time of the outbreak. From 2 to 11 January 2009, 6 patients hospitalized due to chronic pulmonary diseases and located in 2 rooms developed new symptoms of acute lower respiratory tract infection (LRTI) after 6 to 25 days of hospitalization (TAbLE) . Three cases involved male patients sharing the same 3-bed room, followed by 3 cases in a female 3-bed room of the same ward. A nosocomial transmission was first suspected when a characteristic multiresistant S. pneumoniae was isolated from the second patient (case 2) located in the same room as the previous patient (index case) 4 days later. In 4 patients, pneumonia was recognized based on the X-ray pictures, 1 patient had an acute exacerbation of chronic obstructive pulmonary disease (COPD), and 1 patient with asthma had LRTI. Patients' age ranged from 56 to 73 years and all of them had multiple comorbidities such as COPD, diabetes, hypertension, hypothyroidism, obesity, hyperlipidemia, or cardiomyopathy. Patients received extensive antimicrobial treatment before and during arterial hypertension, osteoporosis a the day of hospitalization when new symptoms developed is given in brackets b after 25 days of hospitalization, the patient was discharged from the hospital; however, in the evening of the same day he returned to the hospital with new symptoms c the patient returned to the hospital with new symptoms 2 days after being discharged d the patient died due to the primary disease e antimicrobials were given intravenously, otherwise as indicated Antimicrobials used after the detection of new symptoms are marked in bold.
Abbreviations: AECOPD -acute exacerbation of chronic obstructive pulmonary disease, AMC -amoxicillin/clavulanic acid, AMK -amikacin, CAZ -ceftazidime, CFP/SUL -cefoperazone/sulbactam, CFZ -cefazolin, CIPciprofloxacin, CLR -clarithromycin, CRO -ceftriaxone, DOX -doxycycline, iv -intravenous, LRTI -lower respiratory tract infections, MEM -meropenem, MXF -moxifloxacin, PEN -penicillin G, TZP -piperacillin/tazobactam, VAN -vancomycin pneumococcal disease (IPD) and all-cause-pneumonia among healthy young adults as well as, to a lesser degree, protection against IPD in individuals aged over 65 years. 26 A new possibility to reduce the incidence of pneumococcal infections and carriage appeared with pneumococcal conjugate vaccines, which offer long-term protection for small children and bring an indirect effect of creating a herd immunity, observed also in Poland. 27 Although conjugated vaccines were formulated for pediatric use, recently one of them was registered also for use in adults, which may contribute to the limitation of IPD-associated morbidity and mortality in this population, especially in cases and outbreaks caused by bacteria with decreased susceptibility to antibiotics. In parallel to that, it is necessary to maintain infection control in hospitals, which is a crucial measure for the outbreak recognition and containment. -ST156 clone was characterized by susceptibility to macrolides and tetracycline; however, the representatives of this clone, resistant to these compounds, were observed recently. 21, 22 Isolates belonging to the Spain 9V -ST156 clone occurred also among pneumococci nonsusceptible to ciprofloxacin; however, they did not have the alterations in QRDRs as the ones observed among the outbreak isolates and were levofloxacin-and moxifloxacin-susceptible. 23 These observations further underline the epidemiological importance of Spain 9V -ST156 as being capable of rapid adaptive changes, especially concerning antimicrobial resistance, as observed previously for β-lactams.
20
For 2 patients (cases 1 and 6), combined therapy with 2 antimicrobial agents was administered after isolation of S. pneumoniae. The first patient received ceftriaxone with piperacillin/tazobactam because with the new symptoms, Pseudomonas aeruginosa (the same as from the primary culture at the beginning of the hospitalization) together with S. pneumoniae had been isolated from sputum samples. The S. pneumoniae isolate responsible for case 6 was susceptible to penicillin (1 mg/l) but intermediately susceptible to ceftriaxone (2 mg/l); therefore, an initial therapy with the latter antibiotic was supplemented with penicillin after obtaining the results of susceptibility testing (TAbLE) .
Five of 6 patients affected by the outbreak suffered from COPD, a disease that is the major cause of death and disability throughout the world, and is a risk factor for the acquisition of multidrug--resistant pneumococci.
9, 24 Additionally, isolates of the clone Spain 9V -ST156 are often piliated, which helps them to adhere to human epithelial cells and may facilitate nasopharyngeal colonization. 25 Polysaccharide pneumococcal vaccine (PPV) has been used for many years to limit pneumococcal infections, especially in the at-risk adult population; however, this type of vaccine does not influence colonization. The results of randomized clinical trials with PPV and their meta-analyses have demonstrated protective effect against invasive
